- Home
- About ASF
- What is Autism?
- How Common is Autism?
- Signs and Symptoms of Autism
- Autism Diagnosis
- Following a Diagnosis
- Treatment Options
- Beware of Non-Evidence-Based Treatments
- Statement on Use of Medical Marijuana for People with Autism
- Autism and Vaccines
- Autism Science
- Quick Facts About Autism
- What We Fund
- Get Involved
- Resources
- COVID-19 Resources
- Day of Learning
- Contact Us
Seaside Therapeutics Discontinues Arbaclofen (STX209) Extension Study
Published May 31, 2013
in The Boston Globe
Seaside Therapeutics has discontinued their extension study of Arbaclofen (STX209), a drug that showed promise in treating social impairment related to Fragile X syndrome.
Filed under: Autism News, Autism Research, Autism Science, featured, Social Interaction, Social Skills, Treatment, Treatments